The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.
 
Justin A Call
No Relationships to Disclose
 
Douglas W. Orr
No Relationships to Disclose
 
Ian Churchill Anderson
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); EMD Serono (Inst); Hutchison MediPharma (Inst); Merck (Inst); Seagen (Inst); Turning Point Therapeutics (Inst)
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Zhu Chen
Employment - Daiichi Sankyo Pharmaceutical; ProfoundBio
Stock and Other Ownership Interests - Daiichi Sankyo Pharmaceutical; ProfoundBio
 
Sharon Ma
Employment - ProfoundBio; Seagen
Stock and Other Ownership Interests - ProfoundBio; Seagen
 
Naomi N. H. Hunder
Employment - ProfoundBio; Silverback Therapeutics
Stock and Other Ownership Interests - ProfoundBio; Silverback Therapeutics
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Greenwich LifeSciences (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)